Can CD163 macrophages help select MSS colorectal cancer patients for regorafenib plus avelumab?
How BAF/PBAF chromatin-remodeler mutations predict better checkpoint-inhibitor outcomes — and point toward combination strategies
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
